Cosmo Announces Positive Phase 2 Study of Rifamycin 1% Topically Acting Gel, Meeting the Primary Endpoint in Distal Ulcerative Colitis and Ulcerative Proctitis

(p=0.0190). The therapy represents a new non-immune suppressive treatment modality, designed to achieve delivery to the distal colon with a novel liquid to gel delivery system, and a neutral pH. The ...

Salazar Resources to Begin Drilling the Yumi Gold-Silver Veins at Tarqui, with Porphyry Drilling Planned at Monja, Ecuador

Salazar Resources Limited (TSXV: SRL) (OTCQB: SRLZF) (FSE: CCG) ("Salazar" or the "Company") is pleased to announce its ...
PR Newswire

IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Ther…

OptimUM-01 and OptimUM-02 data supports the broad potential of darovasertib plus crizotinib to drive meaningful clinical ...

Immuneering Has Promising Survival Data, Though Its Cash Discount Needs Scrutiny

Immuneering is developing Atebimetinib for pancreatic cancer. Early clinical data show a median overall survival of 17.3 ...
Bangkok PostOpinion

Trump to Asean: Which side are you on?

President Donald Trump is coming to the region amid expectations that the Association of Southeast Asian Nations (Asean) will ...
Manila Standard

KLEVV Powers Up Your Storage with CRAS C930, C925G and C910G PCIe Gen4 SSDs

KLEVV, a renowned memory and storage brand introduced by Essencore and recognized globally for its high-performance and ...